Venture Partner, Wildcat Venture Partners
Phyllis Whiteley is a Venture Partner with Wildcat Venture Partners and is also a life science consultant. Dr. Whiteley has built a career founded on her passion for personalized medicine, global healthcare, and transformative life science innovations. She brings more than 25 years of experience across academics, biotech, and pharma in R&D, business, and portfolio management and has significant international experience, having established affiliates in Japan and Europe. Her work in pharmacology, immunology, and inflammation has resulted in multiple new chemical entities and publications.
Dr. Whiteley has held numerous executive positions including CEO and Board of Directors. At her previous job as a Venture Partner with Mohr Davidow Ventures, Dr. Whiteley provided hands-on leadership in building and creating companies in diagnostics, life science tools, digital health, and personalized medicine including Verinata Health, acquired by Illumina (NASDAQ: ILMN). Her expertise includes strategic planning, financing, partnerships, restructuring, building executive teams, and M&A. Dr. Whiteley previously co-founded Anaphore, Inc. (now Bird Rock Bio) with 5AM Ventures. Prior to her work in venture capital, Dr. Whiteley was an Officer and Senior Vice President, Business Development, Licensing, and Alliance Management at Perlegen Sciences, Inc. Before joining Perlegen, she served as Vice President, Strategic Portfolio Management for Roche. During her ten years with Roche she held various positions in Business Development based in Basel, Switzerland and R&D leadership positions in the US. Prior to her Roche tenure, Dr. Whiteley held a Senior Research Immunology role with Merck.
Dr. Whiteley currently serves on multiple boards including Balance Therapeutics, RainDance Technologies, Analyte Health (Chair), the Personalized Medicine Coalition (emeritus), UCSF Leadership Council for Global Health, and Springboard Enterprises, where she mentors women executives. Dr. Whiteley serves (Chair) on the advisory board for the University of Texas Horizon Fund. She is also a Global Social Benefit Incubator (GSBI) mentor at Santa Clara University in Santa Clara, California. Dr. Whiteley received her BA in Chemistry and PhD in Pharmacology from Washington University in St. Louis, Missouri.